Particularly, 30% of the patients were found to have JAK2 mutations, and 10% of the patients were found to have NRAS or CSF3R mutations, suggesting that kinase signaling pathways are possibly associated with the progression of AEL. The gene discussed is NRAS; the disease is acute erythroid leukemia.